CN114163380B - Alvacpam intermediate and preparation method and application thereof - Google Patents
Alvacpam intermediate and preparation method and application thereof Download PDFInfo
- Publication number
- CN114163380B CN114163380B CN202111480300.0A CN202111480300A CN114163380B CN 114163380 B CN114163380 B CN 114163380B CN 202111480300 A CN202111480300 A CN 202111480300A CN 114163380 B CN114163380 B CN 114163380B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- reaction
- hours
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 238000006243 chemical reaction Methods 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- 239000011737 fluorine Substances 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 9
- 239000012535 impurity Substances 0.000 claims description 8
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- -1 rhodium bis (1, 5-cyclooctadiene) tetrafluoroborate Chemical compound 0.000 claims description 4
- YQYGPGKTNQNXMH-UHFFFAOYSA-N 4-nitroacetophenone Chemical compound CC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQYGPGKTNQNXMH-UHFFFAOYSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract description 22
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract description 22
- 229960005370 atorvastatin Drugs 0.000 abstract description 22
- 239000002994 raw material Substances 0.000 abstract description 5
- 239000006227 byproduct Substances 0.000 abstract description 4
- 239000000047 product Substances 0.000 abstract description 3
- 230000036632 reaction speed Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 206010047115 Vasculitis Diseases 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- WELNSIYTQJSNRP-UHFFFAOYSA-N 2-fluoro-6-methylbenzoic acid Chemical compound CC1=CC=CC(F)=C1C(O)=O WELNSIYTQJSNRP-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000010948 rhodium Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
- B01J31/1845—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing phosphorus
- B01J31/185—Phosphites ((RO)3P), their isomeric phosphonates (R(RO)2P=O) and RO-substitution derivatives thereof
- B01J31/186—Mono- or diamide derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/60—Reduction reactions, e.g. hydrogenation
- B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
- B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
- B01J2231/645—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/822—Rhodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
The invention provides an atorvastatin intermediate (a compound shown as a formula I), which can be used as an atorvastatin raw material or an intermediate to synthesize atorvastatin. The invention also provides a preparation method of the compound of the atorvastatin intermediate as shown in the formula I, and the compound of the atorvastatin intermediate as a target product is obtained through 3 steps of reactions, so that the whole route is novel in design, the chiral resolution process adopted in the prior art is avoided, the practicability is high, the yield is high, the reaction speed is high, and few byproducts are generated, so that the method is very suitable for industrial application.
Description
Technical Field
The invention relates to atorvastatin, in particular to an atorvastatin intermediate, a preparation method and application thereof.
Background
Atorvastatin is a drug developed by Kai Mo Sente Ricks Inc. of America for the treatment of severe active anti-neutrophil cytoplasmic autoantibody-related vasculitis. Severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis is a rare systemic autoimmune disease involving small blood vessels. Glucocorticoids have been used for decades to treat severe active anti-neutrophil cytoplasmic autoantibody-related vasculitis, and although patient prognosis improves with continued optimization of treatment, long-term use of hormones to produce organ damage and other toxic reactions threatens patient health. Clinical trial data of the phase III of the atorvastatin shows that 26-week remission effect of the atorvastatin on patients with severe active anti-neutrophil cytoplasmic autoantibody-related vasculitis is similar to that of prednisone, and 52-week sustained remission effect of the atorvastatin on patients is obviously superior to that of the prednisone. Thus, atorvastatin can reduce the use of glucocorticoids and even replace hormones, and will initiate a new era of treatment of severe active anti-neutrophil cytoplasmic autoantibody-related vasculitis.
The structural formula of the atorvastatin is as follows:
CN106999481a discloses a process for preparing atorvastatin which is not only tedious in preparation steps but also requires resolution using xylenoyl-L-tartaric acid with low yield of the final product.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a compound (formula I), which can be used as a raw material or an intermediate of the atorvastatin to synthesize the atorvastatin.
Except for special descriptions, the parts are parts by weight, and the percentages are mass percentages.
In order to achieve the above purpose, the technical scheme of the invention is as follows:
a compound of formula I having the formula:
wherein R is 1 Is halogen; r is R 2 Is COR 4 ；R 4 Is halogen or OC 1 -C 6 Alkoxy groups of (a).
In one embodiment, the halogen is selected from fluorine, chlorine, bromine or iodine; fluorine, chlorine or bromine are preferred.
In one embodiment, the OC 1 -C 6 Is selected from methoxy or ethoxy.
In one embodiment, R 1 Is fluorine.
In one embodiment, R 4 Is methoxy.
In one embodiment, R 1 Is fluorine; r is R 2 Is COR 4 ；R 4 Is methoxy.
In one embodiment, the invention also provides the use of a compound of formula I as a starting material or intermediate for atorvastatin.
In one embodiment, the compound I may appear as an impurity in the final product of atorvastatin, and thus the present invention also provides the use of the compound of formula I as an impurity control for atorvastatin.
A compound of formula II having the formula:
wherein R is 1 Is halogen; r is R 2 Is COR 4 ；R 3 Is nitro or amino; r is R 4 Is halogen or OC 1 -C 6 Alkoxy groups of (a).
In one embodiment, the halogen is selected from fluorine, chlorine, bromine or iodine; fluorine, chlorine or bromine are preferred.
In one embodiment, the OC 1 -C 6 Is selected from methoxy or ethoxy.
In one embodiment, R 1 Is fluorine.
In one embodiment, R 4 Is methoxy.
In one embodiment, R 1 Is fluorine; r is R 2 Is COR 4 ；R 3 Is nitro; r is R 4 Is methoxy.
In one embodiment, the compound of formula II may appear as an impurity in the end product of the compound of formula I, and thus the invention also provides for the use of the compound of formula II as a control for the impurity of the compound of formula I.
In one embodiment, the compounds of formula I of the present invention are prepared by reduction of compounds of formula II.
The reduction of the above compounds of formula II to compounds of formula I involves two chiral positions, with simultaneous nitro reduction. It has been found that different catalysts and ligands have a great influence on the reaction, and that once the control is not good, there are cases where there are many byproducts, the yield is low, and the ee value is low. In addition, the reaction conditions also affect the yield and ee value of the product. The inventors have found after a number of experiments that rhodium (I) bis (1, 5-cyclooctadiene) tetrafluoroborate (Rh (COD) is used 2 BF 4 The (R) -Ligand1 is used as a catalyst Ligand, dichloromethane is used as a solvent, the reaction is carried out for 12-24 hours at 20-30 ℃ in hydrogen with 1 atmosphere, few byproducts are produced, the yield of the final product of the compound shown as the formula II is high, and the ee value is high.
The structural formula of the (R) -Ligand1 is as follows:
a compound of formula IV having the formula:
wherein R is 1 Is halogen.
In one embodiment, the compounds of formula II of the present invention are prepared by coupling a compound of formula III with a compound of formula IV, as follows:
in one embodiment, the process for the preparation of the compounds of formula II of the present invention is: dissolving compound III in anhydrous acetone, adding K 2 CO 3 And DMF solution in which compound IV is dissolved, stirring at room temperature for 30-40 hours, adding anhydrous Na 2 SO 4 Then stirring and reacting for 2-5 hours at 40-60 ℃, and then separating to obtain the compound II.
The compound of formula IV may appear as an impurity in the end product of the compound of formula II, and the invention therefore also provides the use of the compound of formula IV as a reference for the impurity of the compound of formula II.
In one embodiment, the IV compound is prepared by reacting a compound of formula VI with a compound of formula V, the reaction formula being as follows:
in one embodiment, the process for preparing the compounds of formula IV of the present invention is: dissolving a compound V (2-fluoro-6-methylbenzoic acid) by using anhydrous THF, cooling to the temperature of between-5 and 0 ℃ in a low-temperature reaction tank, dropwise adding a oxalyl chloride THF solution, moving to the room temperature after the addition, stirring and reacting for 1 to 3 hours, cooling to the temperature of between-5 and 0 ℃ in a reaction system, dropwise adding a pyridine and a compound VI THF solution, moving to the room temperature after the addition, continuing stirring and reacting for 3 to 5 hours, and separating to obtain the compound IV.
The preparation method of the compound III comprises the following steps: under the protection of nitrogen, dropwise adding a THF solution containing methyl chloroformate into the THF solution dissolved with NaH and p-nitroacetophenone, refluxing for 2-4 hours, stopping the reaction by acetic acid after the reaction system is cooled to room temperature, and separating to obtain the compound III.
The beneficial effects are that:
the invention provides a compound (formula I) which can be used as a raw material or an intermediate of the atorvastatin to synthesize the atorvastatin. The invention has novel design of the whole route, avoids the chiral resolution process adopted in the prior art, has strong practicability, high yield, high reaction speed and few byproducts, and is very suitable for industrial application. The present invention uses rhodium (I) bis (1, 5-cyclooctadiene) tetrafluoroborate (Rh (COD) 2 BF 4 The (R) -Ligand1 is used as a catalyst Ligand, dichloromethane is used as a solvent, the chiral reduction is carried out in hydrogen with the pressure of 1 atmosphere at the temperature of 20-30 ℃ for 12-24 hours to prepare the compound with the formula II, the yield of the final product is high, and the ee value is high. The invention obtains the compound of the intermediate formula I of the atorvastatin through 3 steps of reactions, and the total yield can reach 63.59 percent (calculated by 2-fluoro-6-methylbenzoic acid). In summary, the preparation method of the invention has the advantages of simple preparation method, low cost and easy availability of raw materials, mild reaction conditions, no need of large-scale equipment, high yield and high purity of the final product, and is suitable for industrial production.
Detailed Description
The present invention is described in detail below by way of specific examples, which are given herein for the purpose of further illustration only and are not to be construed as limiting the scope of the present invention, as many insubstantial modifications and variations of the present invention will become apparent to those skilled in the art in light of the foregoing disclosure. The raw materials and the reagents used in the invention are all commercial products.
EXAMPLE 1 Synthesis of Compound I
Compounds of formula II (R 1 Is fluorine; r is R 2 Is COR 4 ；R 3 Is nitro; r is R 4 Reduction for methoxy group to prepare the compound of formula I (R) 1 Is fluorine; r is R 2 Is COR 4 ；R 4 Methoxy) reaction scheme is:
in the presence ofRhodium (I) bis (1, 5-cyclooctadiene) tetrafluoroborate (Rh (COD) 2 BF 4 To a reaction flask of 81mg,0.2 mmol) and Ligand (R) -Ligand1 (174 mg,0.4 mmol) in dichloromethane (20 mL) was added a solution of compound II (4 g,10 mmol) in isopropanol (40 mL). Then stirred at room temperature for 18 hours under 1 atm of hydrogen, TLC showed the reaction to be complete. The reaction solution was diluted with 200mL ethyl acetate and then with saturated NaHCO, respectively 3 Aqueous solution (100 mL X2), saturated aqueous NaCl solution (100 mL X2), and the organic layer was washed with anhydrous Na 2 SO 4 After drying, concentration under reduced pressure, the residue was separated by a silica gel column (ethyl acetate/petroleum ether=1/5) to give 3.6g of compound I as a white solid in a yield of 96% and an ee value of 98.8%. H1 NMR (400 mhz, cdcl 3): delta (ppm): 7.52 (M, 1H), 7.32-6.99 (M, 4H), 6.61 (M, 2H), 4.18 (M, 1H), 3.76 (s, 3H), 3.61-3.32 (M, 4H), 2.88 (M, 1H), 2.46 (s, 3H), 2.12 (M, 1H), 1.78-1.61 (M, 3H) MS (M/z) 371 (M+1).
EXAMPLE 2 Synthesis of Compound II
Compounds of formula II (R 1 Is fluorine; r is R 2 Is COR 4 ；R 3 Is nitro; r is R 4 Is methoxy) is prepared from a compound of formula III (R 2 Is COR 4 ；R 3 Is nitro; r is R 4 Is methoxy) and a compound of formula IV (R 1 Fluorine) coupling, the reaction formula is as follows:
4.9g (22 mmol) of Compound III are dissolved in 100mL of anhydrous acetone, and 4.2g (30 mmol) of K are then added 2 CO 3 And 5.5g (20 mmol) of Compound IV in 10mL of DMF are stirred at room temperature for 36 hours, and 5g of anhydrous Na is added 2 SO 4 Stirring was then continued for 3 hours at 50 ℃, TLC showed complete reaction. The residue after concentrating the reaction solution under reduced pressure was added to 200mL of ethyl acetate, washed with saturated NaCl (100 mL of X2) aqueous solution, and the organic layer was washed with anhydrous Na 2 SO 4 The concentrated crude product was filtered after drying and separated by a silica gel column (ethyl acetate/petroleum ether=1/10) to give 6.3g of compound II as a yellow solid in 72% yield. Yellow solid. H1 NMR [ ]400MHz,CDCl3)：δ(ppm)： 8.38(d,J＝8.7Hz,2H),8.01(d,J＝8.7Hz,2H),7.51(m,1H),7.31-7.03(m,2H),3.87-3.60(m, 5H),2.79-2.52(m,5H),1.78-1.55(m,2H).MS(m/z)399(M+1).
EXAMPLE 3 Synthesis of Compound IV
IV Compounds (R) 1 Is fluorine) is prepared from a compound of formula VI and a compound of formula V (R 1 Fluorine) is prepared by the following reaction formula:
into a 250mL dry three-necked flask with magnetic stirring, 50mL of anhydrous THF and 0.2mL of anhydrous DMF, and 3.1g (20 mmol) of Compound V (2-fluoro-6-methylbenzoic acid) were added, the temperature was lowered to 0℃in a low-temperature reaction vessel, and after the addition was completed, a solution of 1.7mL (20 mmol) of oxalyl chloride in THF (15 mL) was added dropwise, and the mixture was stirred at room temperature for 2 hours. After the reaction was cooled to 0deg.C, a solution of 1.7mL (40 mmol) of pyridine and 2.8g (20 mmol) of compound VI in THF (20 mL) was added dropwise, and after the addition was completed, the reaction was allowed to stand at room temperature for 4 hours with stirring, and TLC showed completion of the reaction. 200mL of ethyl acetate was added for dilution, and the mixture was washed with water (100 mL of X2), 2M aqueous NaOH (100 mL of X2), and saturated NaHCO, respectively 3 Aqueous (100 mL X2) and saturated NaCl aqueous (100 mL X2), the organic layer was washed with anhydrous Na 2 SO 4 After drying, concentration gave 5g of compound IV as a white solid in 92% yield. H 1 NMR(400 MHz,CDCl 3 )：δ(ppm)：9.12(s,1H),7.43(m，1H),7.21-6.96(m,2H),3.55-3.39(m,4H), 2.38(s,3H),2.20-2.14(m,2H).MS(m/z)274(M+1),276(M+1).
EXAMPLE 4 Synthesis of Compound III (2-fluoro-6-methylbenzoic acid)
In a 150mL three-port reaction flask with magnetic stirring and nitrogen protection, 1.2g (20 mmol, 60%) of NaH and 3.3g (20 mmol) of p-nitroacetophenone in 40mL of HF solution were added, respectively, followed by dropwise addition of 2.1g (22 mmol) of methyl chloroformate in 20mL of HF solution under magnetic stirring over about 10 minutes. Reflux was continued for 3 hours under magnetic stirring and TLC showed complete reaction. The reaction system is cooled to room temperature, acetic acid is used for stopping the reaction, 200mL of ethyl acetate is added for dilution,then washed with saturated aqueous NaCl solution (100 mL X4), and then with Na 2 SO 4 The crude product obtained after drying and concentration was separated by silica gel column (ethyl acetate/petroleum ether=1/20) to give 3.2g of compound III as a yellow solid with a yield of 72%. H 1 NMR(400MHz,CDCl 3 ): enol delta (ppm): 12.22 (s, 1H), 8.32 (d, j=8.9 Hz, 2H), 7.96 (d, j=8.9 Hz, 2H), 5.78 (s, 1H), 3.84 (s, 3H). MS (M/z) 224 (m+1).
Claims (7)
1. A compound of formula II having the formula:
wherein R is 1 Is halogen; r is R 2 Is COR 4 ；R 3 Is nitro; r is R 4 Is C 1 -C 6 Alkoxy groups of (a).
2. A compound according to claim 1, wherein: the halogen is selected from fluorine, chlorine, bromine or iodine; the C is 1 -C 6 Is selected from methoxy or ethoxy.
3. A compound according to claim 1, wherein: r is R 1 Is fluorine; r is R 2 Is COR 4 ；R 4 Is methoxy.
4. Use of a compound of formula II as claimed in claim 1 as a compound impurity control of formula I;
the compound of formula I has the following structural formula:
wherein R is 1 Is halogen; r is R 2 Is COR 4 ；R 4 Is C 1 -C 6 Alkoxy groups of (a).
5. Use of a compound of formula IV as a compound of formula II impurity control as described in claim 1;
the compound of formula IV has the following structural formula:
wherein R is 1 Is halogen.
6. A process for the preparation of a compound of formula I, characterized in that: the reduction of a compound of formula II according to claim 1 to produce a compound of formula I; the catalyst used for reduction is rhodium bis (1, 5-cyclooctadiene) tetrafluoroborate, the Ligand of the catalyst is (R) -Ligand1, the solvent is methylene dichloride, and the reaction is carried out for 12-24 hours at 20-30 ℃ in hydrogen with 1 atmosphere; the structural formula of the (R) -Ligand1 is as follows:
the compound of formula I has the following structural formula:
7. a process for the preparation of a compound of formula I according to claim 6, wherein: the compound of formula II is prepared by coupling a compound of formula III and a compound of formula IV, and the reaction formula is as follows:
dissolving compound III in anhydrous acetone, adding K 2 CO 3 And DMF solution in which compound IV is dissolved, and adding anhydrous Na after reacting for 30-40 hours at room temperature 2 SO 4 Then continuously reacting for 2-5 hours at 40-60 ℃, and then separating to obtain a compound II;
the IV compound is prepared by reacting a compound of formula VI with a compound of formula V, wherein the reaction formula is as follows:
dissolving a compound V by anhydrous THF, cooling to the temperature of-5-0 ℃ in a low-temperature reaction tank, dropwise adding a oxalyl chloride THF solution, transferring to room temperature for reaction for 1-3 hours after the addition, dropwise adding a pyridine and a compound VI-containing THF solution after the reaction system is cooled to the temperature of-5-0 ℃, transferring to room temperature for continuous reaction for 3-5 hours after the addition, and separating to obtain a compound IV;
the preparation method of the compound III comprises the following steps: under the protection of nitrogen, dropwise adding a THF solution containing methyl chloroformate into the THF solution dissolved with NaH and p-nitroacetophenone, refluxing for 2-4 hours, stopping the reaction by acetic acid after the reaction system is cooled to room temperature, and separating to obtain the compound III.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111480300.0A CN114163380B (en) | 2021-12-06 | 2021-12-06 | Alvacpam intermediate and preparation method and application thereof |
| CN202311336538.5A CN117402104A (en) | 2021-12-06 | 2021-12-06 | Preparation method of chiral intermediate of atorvastatin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111480300.0A CN114163380B (en) | 2021-12-06 | 2021-12-06 | Alvacpam intermediate and preparation method and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311336538.5A Division CN117402104A (en) | 2021-12-06 | 2021-12-06 | Preparation method of chiral intermediate of atorvastatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114163380A CN114163380A (en) | 2022-03-11 |
| CN114163380B true CN114163380B (en) | 2023-11-07 |
Family
ID=80483749
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311336538.5A Pending CN117402104A (en) | 2021-12-06 | 2021-12-06 | Preparation method of chiral intermediate of atorvastatin |
| CN202111480300.0A Active CN114163380B (en) | 2021-12-06 | 2021-12-06 | Alvacpam intermediate and preparation method and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311336538.5A Pending CN117402104A (en) | 2021-12-06 | 2021-12-06 | Preparation method of chiral intermediate of atorvastatin |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN117402104A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102264227A (en) * | 2008-12-22 | 2011-11-30 | 凯莫森特里克斯股份有限公司 | C5ar antagonists |
| CN103068385A (en) * | 2010-06-24 | 2013-04-24 | 凯莫森特里克斯股份有限公司 | C5ar antagonists |
| WO2014187273A1 (en) * | 2013-05-23 | 2014-11-27 | 苏州明锐医药科技有限公司 | Avanafil preparation method |
| CA3179156A1 (en) * | 2020-08-07 | 2022-02-10 | Kira Pharmaceuticals (Suzhou) Ltd. | Compounds as c5ar inhibitors |
| CN114262291A (en) * | 2022-01-04 | 2022-04-01 | 重庆医科大学 | Synthetic method of alvarazepam |
-
2021
- 2021-12-06 CN CN202311336538.5A patent/CN117402104A/en active Pending
- 2021-12-06 CN CN202111480300.0A patent/CN114163380B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102264227A (en) * | 2008-12-22 | 2011-11-30 | 凯莫森特里克斯股份有限公司 | C5ar antagonists |
| CN103068385A (en) * | 2010-06-24 | 2013-04-24 | 凯莫森特里克斯股份有限公司 | C5ar antagonists |
| WO2014187273A1 (en) * | 2013-05-23 | 2014-11-27 | 苏州明锐医药科技有限公司 | Avanafil preparation method |
| CA3179156A1 (en) * | 2020-08-07 | 2022-02-10 | Kira Pharmaceuticals (Suzhou) Ltd. | Compounds as c5ar inhibitors |
| CN114262291A (en) * | 2022-01-04 | 2022-04-01 | 重庆医科大学 | Synthetic method of alvarazepam |
Non-Patent Citations (2)
| Title |
|---|
| 1852299-76-3;Ukrorgsyntez Ltd.;《Stn Registry》;第1页 * |
| Cyclic Enecarbamates as Precursors of alpha,beta-Unsaturated Iminium Ions: Reactivity and Synthesis of 6,6-Spirocyclic Ring Systems;Zhanwei Wang等;《The Journal of Organic Chemistry》;第81卷(第21期);第10366-10375页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117402104A (en) | 2024-01-16 |
| CN114163380A (en) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9663550B2 (en) | Method for preparing abiraterone acetate | |
| WO2011153923A1 (en) | Preparation process of dronedarone and its salts | |
| CN110183445B (en) | Synthetic method of moxifloxacin and derivatives thereof | |
| CN116640088A (en) | Preparation method of high-purity Lei Fen narasin | |
| CN108409602B (en) | Method for preparing α -aryl nitrile compound | |
| CN114163380B (en) | Alvacpam intermediate and preparation method and application thereof | |
| CN100560573C (en) | A kind of preparation method of high purity letrozole | |
| CN109734656B (en) | Preparation method of nitrendipine | |
| CN114262291B (en) | Synthesis method of atorvastatin | |
| US6476250B1 (en) | Optically active fluorinated binaphthol derivative | |
| CN112939814B (en) | Preparation method of deuterated dacarbazine intermediate | |
| CN113024375B (en) | Preparation method of trans, trans-4-alkyl-4' -amyl-3 (E) alkene-bicyclohexane liquid crystal monomer | |
| CN111620788B (en) | Method for preparing (2S,3S) -3-amino-bicyclo [2.2.2] octane-2-formic ether | |
| JP6503227B2 (en) | Purification method of 4-hydroxybenzoic acid long chain ester | |
| CN114014864A (en) | Preparation process of traasiril compound | |
| CN108558974B (en) | Preparation and application of sugar-derived nickel pyridine triazole catalyst | |
| CN113717132A (en) | Key intermediate of antiepileptic drug and preparation method thereof | |
| JP2007231002A (en) | Manufacturing method of polymerizable diamantyl ester compound | |
| CN114874127B (en) | Preparation method of difluoro carbonyl indolone compound | |
| CN113072448B (en) | Aryl gemfibrozil derivative high-valence iodine compound and preparation method thereof | |
| CN112159336B (en) | Preparation method of high-purity aryne substituted nitrile compound | |
| CN108264531B (en) | Preparation method of anecortave acetate | |
| CN112079894B (en) | Preparation method of Levonorgestrel pharmacopoeia impurity V | |
| CN113754715B (en) | Optical selective process synthesis method of (5R) -5-hydroxyl triptolide | |
| CN115286559B (en) | Preparation method of key intermediate of anti-new crown drug Pa Luo Weide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |